

## Catalog # 10-2660

## **Obatoclax**

803712-79-0 GX15-070

2-[2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-3-methoxy-2H-pyrrol-5-yl]-1H-indole methanesulfonate Lot # X105203

A novel Bcl-2 homology domain-3 (BH3) mimetic.<sup>1</sup> Inhibits primary acute myeloid leukemia (AML) progenitor cell proliferation (IC<sub>50</sub>=0.18  $\mu$ M) and induces apoptosis in primary AML cells (IC<sub>50</sub>= 3.6  $\mu$ M)<sup>2</sup>. Synergizes with other agents such as chloroquine<sup>3</sup> and cytarabine<sup>4</sup> in cytotoxicity against a variety of cancer cells. Mediates mitochondrial stress *via* MCL-1 inhibition.<sup>5</sup>

- 1) Chonghaile and Letai (2008), Mimicking the BH3 domain to kill cancer cells; Oncogene, 27 S149
- 2) Konopleva et al. (2008), Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax); Cancer Res., **68** 3413
- 3) Wang et al. (2014), Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells; Oncol. Rep., **32** 2789
- 4) Xie et al. (2015), Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage; Mol. Oncol., **9** 409
- 5) Sulkshane and Teni (2017), BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells; Oncotarget, 8 60060

## **PHYSICAL DATA**

Molecular Weight: 413.50

Molecular Formula:  $C_{20}H_{19}N_3O \cdot CH_3SO_3H$ 

Purity: 98% by TLC

NMR: (Conforms)

Solubility: DMSO (up to 5 mg/ml)

Physical Description: Purple solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.